Moreover, this finding has inspired a competitive inhibition therapy against SARS‐CoV‐2, which uses ACE2‐expressing EVs to occupy SARS‐CoV‐2 S protein S1 domain in a competitive manner, therefore protecting ACE2‐expressing cells from viral infection [51]. This evidence concerns the gene PROS1 and viral infectious disease.